You are here: Welcome » Andrew McRae

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Both sides next revision
andrew_mcrae [2022/10/25 00:46]
liam [Alberta Health Services] 		andrew_mcrae [2022/10/25 00:47] (current)
liam [Ottawa Hospital]
Line 16: Line 16:
 ==== Ottawa Hospital ==== ==== Ottawa Hospital ====
  
-McRae is a collaborator on a project that addresses ethical and policy challenges posed by cluster randomized trials, in partnership with the Rotman Institute of Philosophy and the [[:Ottawa Hospital]] Research Institute, funded by the [[:Canadian Institutes of Health Research]].((//Andrew McRae.// The Rotman Institute of Philosophy. Retrieved January 10, 2022, from https://www.rotman.uwo.ca/portfolio-items/mcrae-andrew/#tab-5d6239302fa152c2ec9))+McRae is a collaborator on a project that addresses ethical and policy challenges posed by cluster randomized trials, in partnership with the Rotman Institute of Philosophy and the [[Ottawa Hospital Research Institute]], funded by the [[Canadian Institutes of Health Research]].((//Andrew McRae.// The Rotman Institute of Philosophy. Retrieved January 10, 2022, from https://www.rotman.uwo.ca/portfolio-items/mcrae-andrew/#tab-5d6239302fa152c2ec9))
  
 The OHRI has received funding for research from [[:pharmaceutical_companies:Pfizer]] for research on drugs for advanced lung cancer,((//Early phase clinical trials shows promising results in advanced lung cancer.// (2011, October 12). Ottawa Hospital Research Institute. https://archive.ph/QMO7q)) kidney transplant patients((Knoll, G. A., Kokolo, M. B., Mallick, R., Beck, A., Buenaventura, C. D., Ducharme, R., Barsoum, R., Bernasconi, C., Blydt-Hansen, T. D., Ekberg, H., Felipe, C. R., Firth, J., Gallon, L., Gelens, M., Glotz, D., Gossmann, J., Guba, M., Morsy, A. A., Salgo, R., & Scheuermann, E. H. (2014). //Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.// BMJ, 349(nov24 1), g6679–g6679. https://doi.org/10.1136/bmj.g6679)) ((Ganton, J. (2015, October 22). //Drugs commonly used in kidney transplant patients not as effective as previously thought.// Ottawa Hospital Research Institute. https://archive.ph/SGtWQ)) and blood clots in cancer patients.((Ganton, J., & Pulkinghorn, I. M. (2018, December 4). //Drug dramatically reduces risk of dangerous blood clots in cancer patients.// Ottawa Hospital Research Institute. https://archive.ph/n6N5h)) ((Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., Trinkaus, M., Tomiak, A., Lee, A. Y. Y., Gross, P. L., Lazo-Langner, A., El-Maraghi, R., Goss, G., Le Gal, G., Stewart, D., & Ramsay, T. (2019). //Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.// The New England Journal of Medicine, 380(8), 711–719. https://doi.org/10.1056/NEJMoa1814468))  The OHRI has received funding for research from [[:pharmaceutical_companies:Pfizer]] for research on drugs for advanced lung cancer,((//Early phase clinical trials shows promising results in advanced lung cancer.// (2011, October 12). Ottawa Hospital Research Institute. https://archive.ph/QMO7q)) kidney transplant patients((Knoll, G. A., Kokolo, M. B., Mallick, R., Beck, A., Buenaventura, C. D., Ducharme, R., Barsoum, R., Bernasconi, C., Blydt-Hansen, T. D., Ekberg, H., Felipe, C. R., Firth, J., Gallon, L., Gelens, M., Glotz, D., Gossmann, J., Guba, M., Morsy, A. A., Salgo, R., & Scheuermann, E. H. (2014). //Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.// BMJ, 349(nov24 1), g6679–g6679. https://doi.org/10.1136/bmj.g6679)) ((Ganton, J. (2015, October 22). //Drugs commonly used in kidney transplant patients not as effective as previously thought.// Ottawa Hospital Research Institute. https://archive.ph/SGtWQ)) and blood clots in cancer patients.((Ganton, J., & Pulkinghorn, I. M. (2018, December 4). //Drug dramatically reduces risk of dangerous blood clots in cancer patients.// Ottawa Hospital Research Institute. https://archive.ph/n6N5h)) ((Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., Trinkaus, M., Tomiak, A., Lee, A. Y. Y., Gross, P. L., Lazo-Langner, A., El-Maraghi, R., Goss, G., Le Gal, G., Stewart, D., & Ramsay, T. (2019). //Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.// The New England Journal of Medicine, 380(8), 711–719. https://doi.org/10.1056/NEJMoa1814468)) 
Back to top